RECORD 3, 2014 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of everolimus versus sunitinib in patients with metastatic renal cell carcinoma


NCT00903175    J Clin Oncol 2014;32:2765-72  

Studied treatment everolimus
Control treatment sunitinib

Patients patients with metastatic renal cell carcinoma
Group sizes238 / 233
treatment line line 1

Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design Cross over
HypotheseNon inferiority

EndpointX1N1X0N0TE95% CI PFS - 238 - 233 1,40[1,14; 1,71] OS - 238 - 233 no data0,22,01,0

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:2765-72     [PMID: 25049330]   link to pdf   add to Mendeley record NCT00903175

Registering number NCT00903175 (see trial on
Code Name